Hydroksychlorochina: interakcje
Hydroksychlorochina (Plaquenil), lek wydłużający odstęp QT: 209 udokumentowanych interakcji w indeksowanych przez nas etykietach FDA i kartach informacyjnych. Poważne: 122, umiarkowane: 58, niewielkie: 29, pary, dla których etykieta nie zgłasza istotnej interakcji: 0. Każda pozycja poniżej cytuje zdanie, na którym się opiera. Ta strona leku to punkt wyjścia, a nie rozstrzygnięcie dla indywidualnej sytuacji.
Interakcje z etykiety
Poważne interakcje (122)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Avoid concomitant use of cimetidine 7.9 Rifampicin Lack of efficacy of hydroxychloroquine was reported when rifampicin was concomitantly administered. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (etykieta leku Emtrycytabina + rylpiwiryna + tenofowir, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (etykieta leku Fosfomycyna, Interakcje z innymi lekami)
(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (etykieta leku Foskarnet, Interakcje z innymi lekami)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
- IwabradynaPoważna
Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etykieta leku Iwabradyna, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (etykieta leku Mirtazapina, Interakcje z innymi lekami)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
- OksaliplatynaPoważna
Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (etykieta leku Oksaliplatyna, Interakcje z innymi lekami)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
- PazopanibPoważna
Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)
- PenicylaminaPoważna
Penicillamine should not be used in patients who are receiving concurrently gold therapy, antimalarial or cytotoxic drugs, oxyphenbutazone or phenylbutazone because these drugs are also associated with similar serious hematologic and renal adverse reactions. (etykieta leku Penicylamina, Środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (etykieta leku Propafenon, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Avoid the concomitant use of drugs known to prolong the QTc interval. (etykieta leku Sertralina, Interakcje z innymi lekami)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
- VepdegestrantPoważna
Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (etykieta leku Vepdegestrant, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Umiarkowane interakcje (58)
Some of the cases were associated with other risk factors for hepatic injury (e.g., alcohol use, concomitant hepatotoxic medications). (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)
Ampicillin In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Ampicillin In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (etykieta leku Arformoterol, Interakcje z innymi lekami)
…ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine Monoamine Oxidase… (etykieta leku Artykaina + adrenalina, Interakcje z innymi lekami)
Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
• Drugs Associated with Methemoglobinemia : Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (etykieta leku Bupiwakaina, Interakcje z innymi lekami)
• Drugs Associated with Methemoglobinemia : Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (etykieta leku Bupiwakaina + adrenalina, Interakcje z innymi lekami)
The risk of combining buprenorphine with other QT-prolonging agents is not known. (etykieta leku Buprenorfina, Ostrzeżenia i środki ostrożności)
The risk of combining buprenorphine with other QT-prolonging agents is not known. (etykieta leku Buprenorfina + nalokson, Ostrzeżenia i środki ostrożności)
…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (etykieta leku Chloroprokaina, Środki ostrożności)
Cyclosporine An increased plasma cyclosporin level was reported when cyclosporin and PLAQUENIL were co-administered. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
QT Interval Prolongation and V entricular A rr h ythmia Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia. (etykieta leku Cynakalcet, Ostrzeżenia i środki ostrożności)
Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Desfluran, Ostrzeżenia i środki ostrożności)
Digoxin Concomitant PLAQUENIL and digoxin therapy may result in increased serum digoxin levels. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval. (etykieta leku Efawirenz, Interakcje z innymi lekami)
QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between EFV and drugs that prolong the QTc interval. (etykieta leku Efawirenz + lamiwudyna + tenofowir, Interakcje z innymi lekami)
- ErybulinaUmiarkowana
QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (etykieta leku Erybulina, Ostrzeżenia i środki ostrożności)
Antimalarial : artemether/lumefantrine ↔ etravirine ↓ artemether ↓ dihydroartemisinin ↓ lumefantrine Caution is warranted when co-administering Etravirine and artemether/lumefantrine as it is unknown whether the decrease in exposure of artemether or its active metabolite, dihydroartemisinin, could result in decreased antimalarial efficacy. (etykieta leku Etrawiryna, Interakcje z innymi lekami)
…prolonged QT interval, 3) treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte… (etykieta leku Fentanyl, Ostrzeżenia i środki ostrożności)
…Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (etykieta leku Formoterol, Interakcje z innymi lekami)
- GoserelinaUmiarkowana
Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Goserelina, Ostrzeżenia i środki ostrożności)
Platelet Inhibitors Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium. (etykieta leku Heparyna, Interakcje z innymi lekami)
This observation should be considered in making clinical decisions regarding patient monitoring when prescribing HYSINGLA ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. (etykieta leku Hydrokodon, Ostrzeżenia i środki ostrożności)
Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Izofluran, Ostrzeżenia i środki ostrożności)
TYKERB may prolong the QT interval in some patients. (etykieta leku Lapatynib, Ostrzeżenia i środki ostrożności)
Antacids and kaolin Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
- LeuprorelinaUmiarkowana
Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Leuprorelina, Ostrzeżenia i środki ostrożności)
Drugs Associated with Methemoglobinemia: Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (etykieta leku Lidokaina + adrenalina, Interakcje z innymi lekami)
…prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sufonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (etykieta leku Lidokaina + prylokaina, Interakcje z innymi lekami)
Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (etykieta leku Lofeksydyna, Ostrzeżenia i środki ostrożności)
Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (etykieta leku Mepiwakaina, Interakcje z innymi lekami)
Methotrexate Concomitant use of PLAQUENIL and methotrexate may increase the incidence of adverse reactions. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (etykieta leku Metronidazol, Interakcje z innymi lekami)
There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (etykieta leku Mifepryston, Ostrzeżenia i środki ostrożności)
Antacids and kaolin Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
- PasyreotydUmiarkowana
Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etykieta leku Pasyreotyd, Interakcje z innymi lekami)
Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (etykieta leku Ponesimod, Interakcje z innymi lekami)
- PrazykwantelUmiarkowana
Praziquantel Chloroquine has been reported to reduce the bioavailability of praziquantel. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
…ropivacaine, tetracaine Antineoplastic Agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration… (etykieta leku Prylokaina + adrenalina, Interakcje z innymi lekami)
Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (etykieta leku Rokuronium, Ostrzeżenia i środki ostrożności)
…ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine NAROPIN should be… (etykieta leku Ropiwakaina, Interakcje z innymi lekami)
…quinidine, tocainide Antibiotics Chloramphenicol, clarithromycin, dapsone, doxycycline; Fluoroquinolones (such as ciprofloxacin) Oral Anticoagulants Warfarin Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol… (etykieta leku Ryfapentyna, Interakcje z innymi lekami)
In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (etykieta leku Rylpiwiryna, Ostrzeżenia i środki ostrożności)
Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Sewofluran, Ostrzeżenia)
- SorafenibUmiarkowana
Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etykieta leku Sorafenib, Ostrzeżenia i środki ostrożności)
- SunitynibUmiarkowana
Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etykieta leku Sunitynib, Interakcje z innymi lekami)
Co-administration of PLAQUENIL with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
- TryptorelinaUmiarkowana
Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Tryptorelina, Ostrzeżenia i środki ostrożności)
…like other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (etykieta leku Umeklidynium + wilanterol, Interakcje z innymi lekami)
Antacids and kaolin Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etykieta leku Zasadowy cytrynian bizmutu + metronidazol + tetracyklina, Ostrzeżenia i środki ostrożności)
Wzmianki o niewielkim znaczeniu (29)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (etykieta leku Pilokarpina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)
Sprawdź, jak Hydroksychlorochina łączy się ze wszystkim, co przyjmujesz. Dodaj całą listę; wszystkie pary są sprawdzane jednocześnie.
Otwórz w wyszukiwarceTo nie jest porada medyczna. Stopień nasilenia odzwierciedla sformułowania etykiety, a nie indywidualne okoliczności. Oznaczenie „poważna” może dotyczyć połączenia stosowanego rutynowo pod nadzorem, a „niewielka” może mieć znaczenie przy dużych dawkach. Należy zapytać farmaceutę.